IGM Biosciences Inc

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IGM Biosciences reports progress in clinical development and strategic shifts

IGM Biosciences showcases progress in clinical development and financial performance.
Strategic shifts towards autoimmune indications present market opportunities.
Management addresses concerns and highlights safety profiles of key product candidates.
Potential for partnerships and differentiation in oncology and autoimmune diseases discussed.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases –

IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business Units

MOUNTAIN VIEW, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021 at 3:20 p.m. EDT.

IGM Biosciences to Present at the 2021 Cantor Virtual Global Healthcare Conference

MOUNTAIN VIEW, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in three upcoming investor conferences:

IGM Biosciences to Participate in Three Upcoming Investor Conferences

– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 –

IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical Officer, effective today. Dr. Takimoto will be responsible for global development of IGM's clinical pipeline of proprietary IgM antibodies. He joins IGM with 30 years of experience in cancer research and development, most recently as Senior Vice President, Oncology, Gilead Sciences, Inc. Daniel S. Chen, M.D., Ph.D., will continue to assist the Company in a consulting capacity.

IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D.

Editas Medicine

Ionis Pharma

Xencor

Zymeworks Inc

These biotech stocks could have great long-term potential.

5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021

Company Expects to Advance First Intranasally Administered IgM Antibody, IGM-6268, into the Clinic in Third Quarter of 2021 Company Expects to Advance First Intranasally Administered IgM Antibody, IGM-6268, into the Clinic in Third Quarter of 2021

IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19

Bed Bath & Beyond

DermTech Inc

Esperion Therapeutics

Fulgent Genetics

GEO Group

GTT Communications

Workhorse Group

Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size of the outstanding short position for a stock might not necessarily be the best indicator of how volatile a stock can be if the shorts begin to cover.

8 Stocks With The Highest Short Interest

IGM Biosciences Announces First Quarter 2021 Financial Results and Provides Corporate Update

HUDDINGE, Sweden, May 5, 2021 /PRNewswire/ -- Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual general meeting in Medivir Aktiebolag (publ) on 5 May 2021 resolved to approve the profit and loss accounts and balance sheets for the financial year 2020. The persons who had been board members and managing directors were discharged from liability with respect to their respective management of the company for the financial year 2020.

Resolutions at the Annual General Meeting in Medivir on 5 May 2021

MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Truist Securities Life Sciences Summit on May 4, 2021 at 4:20 p.m. EDT. The conference will be held in a virtual meeting format.

IGM Biosciences to Present at the Truist Securities Life Sciences Summit

STOCKHOLM, April 20, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)  today announces that the company will participate at the virtual meeting Kempen Life Sciences Conference - 2021 Thematic Virtual Series, on April 21. The presentation will be available via Medivirs website; www.medivir.com.

Medivir to participate at the Kempen Life Sciences Conference

STOCKHOLM, April 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its Board of Directors appoints Magnus Christensen, the company's CFO, as interim CEO of Medivir. Magnus has been CFO of the company since 2019 and will take up his new role in connection with Medivir's Annual General Meeting on May 5, 2021.

Medivir appoints Magnus Christensen as interim CEO

STOCKHOLM, April 6, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2020 now is available at the company's website: www.medivir.com. In the spring of 2020, Medivir was able to present promising data from the phase Ia study and shortly thereafter initiate the phase Ib study with MIV-818, our proprietary and wholly owned candidate drug for liver cancer.

Medivir 2020 Annual Report published

STOCKHOLM, March 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during March 2021 as a result of the previously announced directed issue to Linc AB which in total resulted in an increase of 3,600,000 class B shares. Today, the last trading day of the month, there are in total 55,735,651 shares in Medivir, of which all are class B shares with in total 55,735,651 corresponding voting rights.

Number of shares and votes in Medivir

IGM Biosciences, Inc. (IGMS) CEO Fred Schwarzer on Q4 2020 Results - Earnings Call Transcript

– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 –

IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

STOCKHOLM, March 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study with MIV-818. Like the other patients in the study, the patient is dosed in cycles of three weeks starting with MIV-818 as monotherapy for five days.

Last patient with liver cancer included in the monotherapy part of Medivir's phase Ib study with MIV-818

MOUNTAIN VIEW, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2020 financial results on Tuesday, March 30, 2021.

IGM Biosciences to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 30, 2021

STOCKHOLM, March 22, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that Yilmaz Mahshid leaves the position as CEO of Medivir. The nomination committee proposes that he is elected as Board Member of the company and that Uli Hacksell is elected new Chairman of the Board.

Changes in Medivir's management and Board of Directors

HUDDINGE, Sweden, March 11, 2021 /PRNewswire/ -- Resolution on a directed issue of shares The extraordinary general meeting in Medivir Aktiebolag (publ) on 11 March 2021 resolved, in accordance with the board of directors' proposal, to raise approximately SEK 27,828,000 by a directed issue of not more than 3,600,000 new class B shares. The right to subscribe for the new class B shares in the directed issue is, with deviation from the shareholders' pre-emption rights, granted to LINC AB.

Resolution at the extraordinary general meeting in Medivir on 11 March 2021

STOCKHOLM, March 8, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright Global Life Sciences Conference, March 9-10. The presentation will be available via Medivirs website; www.medivir.com. More...

Medivir to present at the H.C. Wainwright Global Life Sciences Conference

MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 12, 2021 at 2:00 p.m. ET. The conference will be held in a virtual meeting format.

IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

STOCKHOLM, Jan. 12, 2021 /PRNewswire/ -- Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, Inc. (Nasdaq: IGMS), will receive global, exclusive development rights for birinapant, a...

Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant

- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -

News for IGM Biosciences Inc Stock (IGMS)